Labcorp, an American testing laboratories company, said that its board of directors has authorized it to undertake a spin-off of its fully-owned clinical development business to its shareholders via a tax-free deal. The proposed spin-off will result in a couple of standalone, publicly traded firms, which will be Labcorp, a global laboratory business, and the […]
Thermo Fisher Scientific has agreed to acquire PPD, a US-based clinical research services provider, for $47.50 per share or $20.9 billion. The consideration includes assumption of nearly $3.5 billion of the contract research organization’s net debt. Based in North Carolina, PPD caters to the pharma and biotech industry with a variety of clinical research and […]
ICON plc, an Ireland-based contract research organization (CRO), has agreed to acquire PRA Health Sciences in a cash-cum-stock deal worth around $12 billion. PRA Health Sciences is a US-based contract research organization. The consideration to be paid per share is $80 in cash plus 0.4125 shares of ICON plc. According to ICON plc, the deal […]
Eurofins Scientific, a testing laboratories company based in Luxembourg, has agreed to acquire Beacon Discovery, a drug discovery and contract research organization (CRO), engaged in the research of G-Protein Coupled Receptor (GPCR). The financial terms of the deal were not disclosed. The California-based Beacon Discovery will join Eurofins Discovery, a CRO that has a portfolio […]
The Rohatyn Group (TRG), a US asset management firm focusing on emerging markets, has completed an investment in Optimapharm, a contract research organization (CRO) based in Croatia. The Croatian CRO, which was established in 2006, manages clinical trials on behalf of major biotech, pharma, and medical devices companies across 22 countries in Europe. Colin Clark […]
In a strategic move to bolster its position in the pharmaceutical research sector, Charles River Laboratories International, Inc. has agreed to acquire Michigan-based non-clinical contract research organization (CRO), MPI Research, for approximately $800 million. This acquisition is set to enhance Charles River’s capabilities in early-stage drug development and expand its service offerings across the biopharma […]